Treatment of Neuromyelitis Optica

Japanese Journal of Clinical Immunology

Volumn 35, Issue 2, 2012, Pages 129-135

  Fujihara, Kazuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

aquaporin 4; astrocyte; multiple sclerosis; neuromyelitis optica; teratment

Indexed keywords

EID: 84922686013     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.35.129     Document Type: Article

References (35)

1. Lennon, V. A., et al. : A serum autoantibody marker of neuromyelitis optica : Distinction from multiple sclerosis. Lancet 364 : 2106–2112, 2004.
2. Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S. & Hinson, S. R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 : 473–477, 2005.
3. Takahashi, T., et al. : Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO : A study on antibody titre. Brain 130 : 1235–1243, 2007.
4. Nakamura M., et al. : Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol, 248 : 1777–1785, 2010.
5. Nakamura M., et al. : Preferential spinal central gray matter involvement in neuromyelitis optica : An MRI study. J Neurol, 255 : 163–170, 2008.
6. Misu T., Fujihara K., Nakashima I., Sato S., Itoyama Y. : Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology, 65 : 1479–1482, 2005.
7. Takahashi T., Miyazawa I., Misu T., Takano R., Nakashima I., Fujihara K., Tobita M., Itoyama Y. : Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody : A herald of acute exacerbations. J Neurol Neurosurg Psychiatry, 79 : 1075–1078, 2008.
8. Baba T., Nakashima I., Kanbayashi T., Konno M., Takahashi T., Fujihara K., Misu T., Takeda A., Shiga Y., Ogawa H., Itoyama Y. : Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol, 256 : 287–288, 2009.
9. Nakamura M., Misu T., Fujihara K., Miyazawa I., Nakashima I., Takahashi T., Watanabe S., Itoyama Y. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler, 15 : 693–700, 2009.
10. Wingerchuk D. M., Lennon V. A., Pittock S. J., Lucchinetti C. F., Weinshenker B. G. Revised diagnostic criteria for neuromyelitis optica. Neurology 66 : 1485–1489, 2006.
11. Waters P. J., et al. : Serologic diagnosis of NMO : A multicenter comparison of aquaporin-4-IgG assays. Neurology ; 78 : 665–671, 2012.
12. Fujihara K. : Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci, 306 : 183–187, 2011.
13. Misu T., Fujihara K., Nakamura M., Murakami K., Endo M., Konno H., et al. : Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica : A case report. Tohoku J Exp Med 209 : 269–275, 2006.
14. Roemer S. F., Parisi J. E., Lennon V. A., Benarroch E. E., Lassmann H., Bruck W., et al. : Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130 : 1194–1205, 2007.
15. Misu T., Fujihara K., Kakita A., Konno H., Nakamura M., Watanabe S., et al. : Loss of aquaporin-4 in lesions of neuromyelitis optica : Distinction from multiple sclerosis. Brain 130 : 122–334, 2007.
16. Misu T., Takano R., Fujihara K., Takahashi T., Sato S., Itoyama Y. : Marked Increase of CSF GFAP in neuromyelitis optica—an astrocytic damage marker. J Neurol Neurosurg Psychiatry 80 : 575–577, 2009.
17. Takano R., Misu T., Takahashi T., Sato S., Fujihara K., Itoyama Y. : Astrocytic damage is far severer than demyelination in NMO : A clinical CSF biomarker study. Neurology 75 : 208–216, 2010.
18. Hinson S. R., Pittock S. J., Lucchinetti C. F., et al. : Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69 : 2221–2231, 2007.
19. Kinoshita M., Nakatsuji Y., Moriya M., et al. : Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 20: 508–512, 2009.
20. Kinoshita M., Nakatsuji Y., Kimura T., et al. : Neuromyelitis optica : Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 386 : 623–627, 2009.
21. Bennett J. L., Lam C., Kalluri S. R., et al. : Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66 : 617–629, 2009.
22. Bradl M., Misu T., Takahashi T., et al. : Neuromyelitis optica : Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66 : 630–643, 2009.
23. Kinoshita M., Nakatsuji Y., Kimura T., et al. : Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun 394: 205–210, 2010.
24. Nishiyama, S., et al. : A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 72 : 1960–1961, 2009.
25. Uzawa, A., et al. : Cytokine and chemokine profiles in neuromyelitis optica : Significance of interleukin-6. Mult Scler 16 : 1443–1452, 2010.
26. Chihara, N., et al. : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 108 : 3701–3706, 2011.
27. Kim W., Kim S. H., Nakashima I., Takai Y., Fujihara K., Leite M. I., Kitley J., Palace J., Santos E., Coutinho E., Silva A. M., Kim B. J., Kim B. J., Ahn S. W., Kim H. J. : Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology in press.
28. Carroll W. M., Fujihara K. Neuromyelitis optica. Curr Treat Options Neurol, 12 : 244–255, 2010.
29. Sato D., Callegaro D., Lana-Peixoto M. A., Fujihara K on behalf of BCTRIMS. : Treatment of neuromyelitis optica, an evidence based review. Arq Neuropsiquiatr in press.
30. Watanabe S., Nakashima I., Misu T., Miyazawa I., Shiga Y., Fujihara K., Itoyama Y. : Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler, 13 : 128–132, 2007.
31. Cortese, I., et al. : Evidence-based guideline update : Plasmapheresis in neurologic disorders : Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 76 : 294–300, 2011.
32. Jacob, A., et al. : Treatment of neuromyelitis optica with rituximab : Retrospective analysis of 25 patients. Arch Neurol 65 : 1443–1448, 2008.
33. Tanaka, M., Tanaka, K. & Komori, M. : Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol 62 : 167–170, 2009.
34. Ishizu, T., et al. : Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128 : 988–1002, 2005.
35. Axtell, R. C., et al. : T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16 : 406–412, 2010.